Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Ovid Therapeutics' Share-based Compensation fell 1521.41% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 2840.56%. This contributed to the annual value of $6.3 million for FY2024, which is 1385.04% down from last year.
  • Per Ovid Therapeutics' latest filing, its Share-based Compensation stood at $1.1 million for Q3 2025, which was down 1521.41% from $1.2 million recorded in Q2 2025.
  • Ovid Therapeutics' Share-based Compensation's 5-year high stood at $2.0 million during Q1 2024, with a 5-year trough of $1.1 million in Q3 2025.
  • Its 5-year average for Share-based Compensation is $1.5 million, with a median of $1.3 million in 2022.
  • Per our database at Business Quant, Ovid Therapeutics' Share-based Compensation tumbled by 5558.85% in 2021 and then soared by 5337.17% in 2022.
  • Over the past 5 years, Ovid Therapeutics' Share-based Compensation (Quarter) stood at $1.3 million in 2021, then surged by 31.51% to $1.7 million in 2022, then rose by 3.43% to $1.8 million in 2023, then decreased by 29.57% to $1.3 million in 2024, then decreased by 11.98% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.2 million for Q2 2025, and $1.3 million during Q1 2025.